title: Kidney cancer: No advantage of adjuvant sunitinib or sorafenib.
authors.forename: Louise
authors.initials: L
authors.lastname: Stone
mesh_terms: D000970:Antineoplastic Agents; D002292:Carcinoma, Renal Cell; D006801:Humans; D007211:Indoles; D007680:Kidney Neoplasms; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D000077157:Sorafenib; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib